There are eight hallmark biological capabilities necessary for cancer development and persistence: (1) sustained proliferation, (2) evasion of growth suppressors, (3) death resistance …
Mike Hernandez did well for himself and his family. He retired to his home in Coppell at 47 after a career with Lucent Technologies. Five years later, though, doctors found cancer in his throat.
The personalization of oncology treatments demands the alignment of patients’ molecular cancer growth mechanisms with the drugs which have been designed to target the cancer specific molecular signals.
Vertically Integrated Translational Studies of PDX1 as a Therapeutic Target for Pancreatic Cancer via a Novel Bifunctional RNAi Platform.
Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors.
Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors.
Summary of bi-shRNAfurin/GM-CSF Augmented Autologous Tumor Cell Immunotherapy (FANG™) in Advanced Cancer of the Liver.